Search
Tafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Prademagene zamikeracel
go.drugbank.com/drugs/DB17895ApprovedInvestigational[A273833,A273838] Patient cells are then transduced ex vivo with a replication-incompetent retroviral vector (RVV) containing the full-length COL7A1 gene, resulting in cells that express functional collagen … Prademagene zamikeracel is a sheet-based gene therapy comprising autologous cells isolated from skin punch biopsies of patients with mutations in the collagen type VII alpha 1 chain (COL7A1) gene.
Synonyms: EB 101, EB-101Labetalol
go.drugbank.com/drugs/DB00598ApprovedInvestigational[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724] … Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.
Products: Labetalol HCl in Dextrose, Labetalol HCl in Sodium ChlorideGadoquatrane
go.drugbank.com/drugs/DB33282Approved[L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity … in the central nervous system and in the body.
Lonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigational[L36380,L10971] Lonapegsomatropin was granted FDA approval on 25 August 2021.[L36380] It was later approved by the European Commission on 13 January 2022.[L39900] … [A237605,L36380,L36405] Unlike somatropin, which requires daily dosing, lonapegsomatropin can be administered as a single weekly dose.
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawncholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.
Tapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalTapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. … [L41845, A248790] Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in _Photorhabdus luminescens_, a gram-negative bacillus that lives symbiotically with the _
Gatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnGatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. … patients taking gatifloxacin compared to those on macrolide antibiotics.
Categories: Compounds used in a research, industrial, or household settingHuman cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedAfter the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.
Dexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnFor a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. … Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug.
Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamine, (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine